Accès ouvert
2025
conference-abstract
OpenAlex
Éric Durot, Lukshe Kanagaratnam, Sylvain Choquet, Pierre Sesques et autres
Abstract Introduction: The prognosis of patients (pts) with histological transformation (HT) of Waldenström macroglobulinemia (WM) remains dismal with standard chemoimmunotherapy. CD19-targeted chimeric antigen receptor T-cell therapies (CAR-T) can lead to durable responses in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) and are approved …
fr, us, it, gb
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Morgane Cheminant, Roch Houot, Elodie Gat, Catherine Thiéblemont et autres
ABSTRACT: Brexucabtagene autoleucel (brexu-cel) is the anti-CD19 chimeric antigen receptor CAR T-cell (CAR-T) therapy approved for the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL). Our study, conducted in the scope of the French DESCAR-T registry, aimed to analyze outcomes of MCL …
fr, us
(code pays fourni par la source)
2025
article
OpenAlex
Hedi Bensaber, Emmanuelle Ferrant, Rémy Duléry, David Beauvais et autres
All data generated or analysed during this study are subject to controlled access by the Lymphoma Academic Research Organization (LYSARC) owing to privacy and legal requirements and proprietary reasons. LYSARC data can be re-used for the purposes of conducting research in the …
fr
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Xavier Phina-Ziebin, Emmanuel Bachy, François‐Xavier Gros, Roberta Di Blasi et autres
ABSTRACT: High-grade B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements (double hit [HGBL-DH] or triple hit [HGBL-TH]) or not otherwise specified (HGBL-NOS) are considered to be more aggressive diseases among large B-cell lymphomas (LBCLs). CD19-targeting chimeric antigen receptor (CAR) T …
fr
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Nicolas Gower, Cécile Pizot, Marie-Émilie Dourthe, Thomas Gastinne et autres
Introduction: CAR T-cell therapy has emerged as a key treatment for patients with relapsed/refractory B-cell malignancies but is associated with significant side-effects. While cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS) are the most notable and well characterized toxicities, data …
fr
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Morgane Cheminant, Roch Houot, Elodie Gat, Catherine Thiéblemont et autres
Introduction: Since 2020, Chimeric antigen receptor T-cell (CAR-T), namely Brexucabtagene autoleucel (Brexu-Cel), is approved for mantle cell lymphoma (MCL) patients in relapsed or refractory (RR) post BTK inhibitors (BTKi), based on significant complete and duration of response (DOR) in ZUMA-2 trial (Wang …
fr
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Loïc Chartier, Aurélien Belot, Isabelle Chaillol, Mad-Hélénie Elsensohn et autres
Understanding the differences between prognostic and predictive indices is imperative for medical research advances. We have developed a new prognostic measure that will identify the strengths, limitations, and potential applications in clinical practice.
fr
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Xavier Phina-Ziebin, Emmanuel Bachy, Francois Xavier Gros, Roberta Di Blasi et autres
Introduction : High-Grade-B-cell Lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL double hit [HGBL-DH] or HGBL triple hit [HGBL-TH]), or not otherwise specified (HGBL NOS), are distinct subtypes among Large B-Cell lymphoma (LBCL) considered to be more aggressive diseases. These entities …
fr
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Emmanuel Itti, Paul Blanc‐Durand, Alina Berriolo-Riedinger, Salim Kanoun et autres
The GAINED phase 3 trial (ClinicalTrials.gov identifier: NCT01659099) evaluated a PET-driven consolidative strategy in patients with diffuse large B-cell lymphoma. In this post hoc analysis, we aimed to compare the prognostic value of the per-protocol PET interpretation criteria (Menton 2011 consensus) with …
fr
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi, Pierre Sesques et autres
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this study, we analyzed the outcome of 809 patients with R/R DLBCL after two or more previous lines of treatment …
fr
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Roberta Di Blasi, Steven Le Gouill, Emmanuel Bachy, Guillaume Cartron et autres
Anti-CD19 chimeric antigen receptor (CAR) T-cells represent a major advance in the treatment of relapsed/refractory aggressive B-cell lymphomas. However, a significant number of patients experience failure. Among 550 patients registered in the French registry DESCAR-T, 238 (43.3%) experienced progression/relapse, with a median …
fr
(code pays fourni par la source)